Home > Insider Trading > Filing (0001437749-16-043586)

Filing Details

Issuer

Cik	Name	Symbol	Sector (SIC)	IRS No
1586049	Oxford Immunotec Global Plc	OXFD	In Vitro & In Vivo Diagnostic Substances (2835)	000000000

Insiders

Cik	Name	Reported Address	Insider Title	Director	Officer	Large Shareholder	Other
1592286	Peter Wrighton-Smith	C/O Oxford Immunotec Global Plc 94C Innovation Drive Abingdon, Oxfordshire X0 OX14 4RZ	Chief Executive Officer	Yes	Yes	No	No

Reported Non-Derivative Transactions

Sec. Name	Acquisiton - Disposition	Date	Amount	Price	Remaning Holdings	Equity Swap Involved	Form Type	Code	Nature of Ownership	Explanation
Ordinary Shares	Acquisiton	2016-12-16	7,052	$0.81	450,366	No	4	M	Direct
Ordinary Shares	Disposition	2016-12-16	7,052	$15.07	443,314	No	4	S	Direct

Equity Swap Involved	Form Type	Code	Nature of Ownership	Explanation
No	4	M	Direct
No	4	S	Direct

Reported Derivative Transactions

Sec. Name	Sec. Type	Acquisiton - Disposition	Date	Amount	Price	Amount - 2	Price - 2
Ordinary Shares	Stock Option (Right to Buy)	Disposition	2016-12-16	7,052	$0.00	7,052	$0.81

Remaning Holdings	Exercise Date	Expiration Date	Equity Swap Involved	Transaction Form Type	Transaction Code	Nature of Ownership
101,438		2020-02-17	No	4	M	Direct

Footnotes

The original exercise price of these options was priced in GBP0.51 and converted to US$ at an exchange rate of US$1.58823=1GBP.
The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on March 10, 2015, as amended.
The price reported for the sales on December 16, 2016 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $15.00 to $15.10 per share, inclusive. The reporting person undertakes to provide Oxford Immunotec Global PLC, or any of its security holders, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in footnote (3) to this Form 4.
Exercise from an option granted February 28, 2013, which became fully vested on April 1, 2014.